Bolt Biotherapeutics Appoints Nicole Onetto, M.D., to Board of Directors
December 16, 2021 08:00 ET
|
Bolt Biotherapeutics, Inc.
REDWOOD CITY, Calif., Dec. 16, 2021 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the...
Bolt Biotherapeutics Reports Interim BDC-1001 Phase 1/2 Data Demonstrating a Safe and Well-tolerated Profile and Emerging Clinical Activity at the ESMO Immuno-Oncology Congress 2021
December 06, 2021 06:00 ET
|
Bolt Biotherapeutics, Inc.
Company to continue monotherapy dose-escalation and evaluate weekly dose regimen Combination dose-escalation study of BDC-1001 with Opdivo® on target to initiate by year end 2021 Live conference...
Bolt Biotherapeutics to Present Interim Clinical Data on BDC-1001 Phase 1/2 Clinical Trial at ESMO Immuno-Oncology Congress 2021
December 02, 2021 06:00 ET
|
Bolt Biotherapeutics, Inc.
REDWOOD CITY, Calif., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that...
Bolt Biotherapeutics Announces Changes to its Board of Directors
November 19, 2021 08:00 ET
|
Bolt Biotherapeutics, Inc.
REDWOOD CITY, Calif., Nov. 19, 2021 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the...
Bolt Biotherapeutics to Present at Stifel 2021 Virtual Healthcare Conference
November 08, 2021 08:00 ET
|
Bolt Biotherapeutics, Inc.
REDWOOD CITY, Calif., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the...
Bolt Biotherapeutics to Present Updates on Three Pipeline Programs at the 2021 Society for Immunotherapy of Cancer Annual Meeting (SITC)
October 01, 2021 08:00 ET
|
Bolt Biotherapeutics, Inc.
REDWOOD CITY, Calif., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that...
Bolt Biotherapeutics Announces Clinical Collaboration with Bristol Myers Squibb to Study BDC-1001 in Combination with Opdivo® for Treatment of HER2-Expressing Solid Tumors
September 08, 2021 07:30 ET
|
Bolt Biotherapeutics, Inc.
REDWOOD CITY, Calif., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that...
Bolt Biotherapeutics to Participate in Upcoming September Investor Conferences
September 02, 2021 08:00 ET
|
Bolt Biotherapeutics, Inc.
REDWOOD CITY, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the...